21.714 articles found

Manganese increases L-DOPA auto-oxidation in the striatum of the freely moving rat: potential implications to L-DOPA long-term therapy of Parkinson's disease.

Serra PA, Esposito G, Enrico P, Mura MA, Migheli R, Delogu MR, Miele M, Desole MS, Grella G, Miele E.

Br J Pharmacol · 2000-06-01

DOI: 10.1038/sj.bjp.0703379PMID: 10864903

Population pharmacokinetics of levodopa in patients with Parkinson's disease treated with tolcapone.

Jorga K, Banken L, Fotteler B, Snell P, Steimer JL.

Clin Pharmacol Ther · 2000-06-01

DOI: 10.1067/mcp.2000.106795PMID: 10872643

Alpha-dihydroergocryptine in the treatment of de novo parkinsonian patients: results of a multicentre, randomized, double-blind, placebo-controlled study.

Bergamasco B, Frattola L, Muratorio A, Piccoli F, Mailland F, Parnetti L.

Acta Neurol Scand · 2000-06-01

DOI: 10.1034/j.1600-0404.2000.90295a.xPMID: 10877152

Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease.

Kaakkola S.

Drugs · 2000-06-01

DOI: 10.2165/00003495-200059060-00004PMID: 10882160

Levodopa-responsive dystonia. GTP cyclohydrolase I or parkin mutations?

Tassin J, Dürr A, Bonnet AM, Gil R, Vidailhet M, Lücking CB, Goas JY, Durif F, Abada M, Echenne B, Motte J, Lagueny A, Lacomblez L, Jedynak P, Bartholomé B, Agid Y, Brice A.

Brain · 2000-06-01

DOI: 10.1093/brain/123.6.1112PMID: 10825351

Factors affecting levodopa effects in Parkinson's disease.

Ogawa N.

Acta Med Okayama · 2000-06-01

DOI: 10.18926/amo/32303PMID: 10925733

Too many treatments for Parkinson's disease: how should they be used?

Reynolds NC, Terry LC, Mark LP, Prieto TE, Mueller WR.

WMJ · 2000-06-01

PMID: 10927984

Parkinson's disease: a neurodegenerative disease particularly amenable to gene therapy.

Bohn MC.

Mol Ther · 2000-06-01

DOI: 10.1006/mthe.2000.0078PMID: 10933972

Bromocriptine markedly suppresses levodopa-induced abnormal increase of dopamine turnover in the parkinsonian striatum.

Ogawa N, Tanaka K, Asanuma M.

Neurochem Res · 2000-06-01

DOI: 10.1023/a:1007530720544PMID: 10943992

Delta-opioid receptor agonists as a therapeutic approach in Parkinson's disease.

Hill MP, Hille CJ, Brotchie JM.

Drug News Perspect · 2000-06-01

PMID: 12937640

Levodopa/carbidopa/entacapone pharmaceutical composition

KALLIOINEN SARI, KERVINEN LASSE, LAAKSONEN MARJA, LINTULAAKSO JARMO, NISKANEN MARVI.

· 2000-05-26

Drug treatment of Parkinson's disease. Time for phase II.

Drukarch B, van Muiswinkel FL.

Biochem Pharmacol · 2000-05-01

DOI: 10.1016/s0006-2952(99)00340-8PMID: 10704931